Get the Stockscreener App
15.55
5.01%
-0.82
After Hours:
15.55
Syndax Pharmaceuticals Inc stock is traded at $15.55, with a volume of 1.71M.
It is down -5.01% in the last 24 hours and up +19.89% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
See More
Previous Close:
$16.37
Open:
$16.42
24h Volume:
1.71M
Relative Volume:
0.78
Market Cap:
$1.34B
Revenue:
$139.71M
Net Income/Loss:
$-209.36M
P/E Ratio:
-5.2534
EPS:
-2.96
Net Cash Flow:
$-160.60M
1W Performance:
-8.74%
1M Performance:
+19.89%
6M Performance:
+18.52%
1Y Performance:
-13.56%
1-Day Range:
$15.53
$16.50
1-Week Range:
$15.53
$17.08
52-Week Range:
$8.58
$22.50
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
15.55 | 1.36B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
Polar Asset Management Partners Inc. Has $1.31 Million Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax resumed with Buy at Stifel on newly launched drugs - MSN
Syndax Pharmaceuticals (NASDAQ:SNDX) Now Covered by Analysts at Stifel Nicolaus - MarketBeat
Zimmer Partners LP Buys Shares of 213,159 Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Exome Asset Management LLC Has $4.14 Million Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals, Inc. $SNDX Shares Bought by Parkman Healthcare Partners LLC - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Michael A. Metzger Sells 157,307 Shares - MarketBeat
Syndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRC (SNDX) - Seeking Alpha
SNDX: Stifel Reinstates 'Buy' Rating with $44 Price Target | SND - GuruFocus
Stifel Initiates Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Announces Target Price $44 - 富途牛牛
Syndax (SNDX) Gains "Buy" Rating from Stifel, Eyeing Major Growt - GuruFocus
Stifel resumes Syndax Pharmaceuticals stock coverage with Buy rating By Investing.com - Investing.com Canada
Syndax Pharmaceuticals, Inc. $SNDX Shares Sold by Granahan Investment Management LLC - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Now Covered by Guggenheim - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Fibonacci Retracement Aligns with Support in Syndax Pharmaceuticals Inc.Options Play & Risk Managed Investment Signals - beatles.ru
Ieq Capital LLC Invests $727,000 in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals at H.C. Wainwright: Strategic Growth and Profitability By Investing.com - Investing.com Canada
Is Syndax Pharmaceuticals Inc. stock a value trapQuarterly Portfolio Report & Free Daily Entry Point Trade Alerts - beatles.ru
Invesco Ltd. Has $944,000 Stake in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $24.00 - Defense World
Is Syndax Pharmaceuticals Inc. stock forming a triangle patternLayoff News & Community Trade Idea Sharing - beatles.ru
Should I invest in Syndax Pharmaceuticals Inc. before earnings2025 Top Decliners & Stock Timing and Entry Methods - beatles.ru
Will Syndax Pharmaceuticals Inc. Benefit From Sector TailwindsWatch List & Daily Oversold Stock Bounce Ideas - beatles.ru
Syndax Pharmaceuticals Reports Inducement Grants Under - MSN
When Will Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Turn A Profit? - simplywall.st
Trexquant Investment LP Decreases Stock Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Palo Alto Investors LP Has $5.46 Million Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Point72 Europe London LLP Acquires Shares of 184,683 Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Wellington Management Group LLP Sells 4,198,493 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Why is Syndax Pharmaceuticals Inc. stock going downEarnings Growth Summary & Weekly Stock Performance Updates - خودرو بانک
How does Syndax Pharmaceuticals Inc. perform in inflationary periodsJuly 2025 Levels & Real-Time Stock Price Movement Reports - خودرو بانک
What chart patterns are forming on Syndax Pharmaceuticals Inc.July 2025 Selloffs & Entry Point Confirmation Signals - خودرو بانک
Does Syndax Pharmaceuticals Inc. meet Warren Buffett’s criteriaJuly 2025 News Drivers & Technical Buy Zone Confirmation - خودرو بانک
Can Syndax Pharmaceuticals Inc. deliver consistent dividendsJuly 2025 Recap & Fast Moving Market Watchlists - خودرو بانک
Syndax Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | SNDX Stock News - GuruFocus
Syndax Pharmaceuticals' Strategic Use of Inducement Grants to Fuel Long-Term Growth - AInvest
What’s the profit margin of Syndax Pharmaceuticals Inc.2025 EndofYear Setup & Short-Term High Return Strategies - خودرو بانک
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Cancer Drug Developer Syndax Awards 167,400 Stock Options in Major Employee Expansion - Stock Titan
Is Syndax Pharmaceuticals Inc. forming a double bottomQuarterly Profit Report & Stepwise Swing Trade Plans - خودرو بانک
Signal strength of Syndax Pharmaceuticals Inc. stock in tech scannersJuly 2025 Decliners & Weekly High Potential Stock Alerts - Newser
Is a relief rally coming for Syndax Pharmaceuticals Inc. holdersInsider Buying & Real-Time Stock Price Movement Reports - Newser
Should I trade or invest in Syndax Pharmaceuticals Inc.July 2025 Short Interest & Weekly High Return Stock Opportunities - خودرو بانک
Goldman Sachs Raises Price Target on Syndax Pharmaceuticals (SND - GuruFocus
Does Syndax Pharmaceuticals Inc. have consistent dividend growthJuly 2025 Technicals & Risk Adjusted Swing Trade Ideas - خودرو بانک
Goldman Sachs Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Raises Target Price to $24 - 富途牛牛
Can a trend reversal in Syndax Pharmaceuticals Inc. lead to recoveryJuly 2025 Levels & Real-Time Stock Movement Alerts - Newser
Will Syndax Pharmaceuticals Inc. benefit from macro trendsEarnings Miss & Community Verified Trade Signals - Newser
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):